Khadija Saeed

Khadija Saeed

Khadija Saeed is a financial markets reporter at TS2.tech, specializing in stocks, technology and emerging industries. She studied economics and finance at the London School of Economics and previously worked in market research before moving into financial journalism. Her coverage focuses on the companies, innovations and economic trends influencing global investors. Follow Khadija Saeed on Google News.

CRWV Stock Jumps Before Earnings: Why Meta’s $21 Billion AI Deal Has Wall Street Watching

CRWV Stock Jumps Before Earnings: Why Meta’s $21 Billion AI Deal Has Wall Street Watching

CoreWeave shares pushed higher in early U.S. trading Tuesday, recapturing market focus just before the AI cloud firm’s May 7 earnings. Investors zeroed in on an expanded contract backlog, now shored up by Meta Platforms. After sliding alongside other AI infrastructure names on worries over spending from major clients, CRWV was back in view.
5 May 2026
····
Pfizer Earnings Beat Wall Street, But The Patent Cliff Is Still The Story

Pfizer Earnings Beat Wall Street, But The Patent Cliff Is Still The Story

Pfizer turned in a first-quarter profit that beat forecasts on Tuesday, thanks in large part to solid demand for established drugs like the blood thinner Eliquis and cancer therapy Padcev, cushioning the impact of another steep fall in sales of its COVID offerings. Adjusted earnings landed at 75 cents per share, with revenue reaching $14.45 billion—both topping Wall Street’s consensus for 72 cents per share and $13.79 billion in revenue, according to Reuters.
5 May 2026
···
US Stock Market Today: Dow, S&P 500 and Nasdaq Futures Rise as Oil Pullback Gives Wall Street a Narrow Opening

US Stock Market Today: Dow, S&P 500 and Nasdaq Futures Rise as Oil Pullback Gives Wall Street a Narrow Opening

Tuesday morning saw U.S. stock index futures ticking higher, with oil prices dropping back slightly after Middle East jitters dragged the S&P 500 off its highs the previous day. By 5:35 a.m. ET, Dow e-minis had added 124 points, or 0.25%. S&P 500 e-minis were 0.33% higher, while Nasdaq 100 e-minis picked up 0.58%. Brent crude slipped but remained above the $110 mark.
5 May 2026
···
Powell Industries’ $400 Million Data Center Order Puts Its AI Power Boom to the Test

Powell Industries’ $400 Million Data Center Order Puts Its AI Power Boom to the Test

Powell Industries Inc. reported Monday that new orders for its fiscal second quarter surged 97% to $490 million, while backlog climbed to $1.8 billion. That gives the Houston-based electrical-equipment maker a clearer revenue pipeline, even as quarterly profit declined. After the quarter wrapped, Powell landed a data center order topping $400 million.
5 May 2026
··
Sterling Infrastructure Stock Jumps as Data-Center Work Drives Q1 Beat, 2026 Outlook Raise

Sterling Infrastructure Stock Jumps as Data-Center Work Drives Q1 Beat, 2026 Outlook Raise

Sterling Infrastructure shares surged roughly 19% in late Monday trading, after the company topped first-quarter profit forecasts and boosted its full-year guidance—fueled in part by strong demand from the data center and semiconductor sectors. The stock last traded at $631.05 as of 5:42 p.m. ET, up sharply from a $529.49 close, according to MarketBeat.
5 May 2026
···
XCF Global’s Reno Restart Test: June SAF Launch Carries a $120 Million Revenue Goal

XCF Global’s Reno Restart Test: June SAF Launch Carries a $120 Million Revenue Goal

XCF Global on Monday said it’s planning to bring its New Rise Renewables Reno plant back online in June, outlining ambitious 2027 goals that would shift the Nasdaq-listed SAF producer from initial ramp-up into true commercial territory. Management is targeting net revenue between $110 million and $120 million and sees renewable fuel output ranging from 40 million to 43 million gallons for the year ending Dec. 31, 2027.
4 May 2026
·
Mirum Stock Jumps After Volixibat Trial Win Puts First PSC Itch Drug Within Reach

Mirum Stock Jumps After Volixibat Trial Win Puts First PSC Itch Drug Within Reach

Shares of Mirum Pharmaceuticals surged Monday, after the company announced its experimental therapy volixibat hit the primary endpoint in a Phase 2b study targeting primary sclerosing cholangitis, or PSC—a rare liver condition marked by scarring of the bile ducts and potential liver failure. The study zeroed in on cholestatic pruritus, the intense itching caused by impaired bile flow and notorious as one of PSC’s toughest symptoms.
4 May 2026
··
1 … 112 113 114 115 116 … 891
Follow on Google News
Add as preferred source Open in Google News
AI PORTFOLIO

Top Stock Picks

Today’s highest-ranked model selections.

#1 STRONG BUY

CACI International

NYSE: CACI 95 / 100
#2 BUY

Constellation Energy

NASDAQ: CEG 93 / 100
#3 BUY

AerCap

NYSE: AER 91 / 100
#4 BUY ON PULLBACK

Motorola Solutions

NYSE: MSI 89 / 100
#5 ACCUMULATE

Walt Disney

NYSE: DIS 87 / 100
View full portfolio
Editorial model selection. Not personalised advice.